Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation (LUMASCAN-2)

Bronchopulmonary Cancer Screening Program and Primary Cardiovascular Prevention, Early Management of COPD and Smoking Cessation

The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France.

In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years.

Study Overview

• Status: Not yet recruiting
• Conditions: the Rate of Participation in Screening for PBC
• Intervention / Treatment: Other: screening for bronchopulmonary cancer

Detailed Description

The patients will be recruited by correspondence by by sending a letter from the Regional Center for Cancer Screening in Ile de France.

When the patient has agreed to participate, a screening program will be carried out The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Sébastien Gendarme, MD; Phone Number: 01.57.02.20.90; Email: sebastien.gendarme@chicreteil.fr
• Study Contact Backup: Name: Camille JUNG; Phone Number: 0145175000; Email: camille.jung@chicreteil.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 74 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Subjects aged 55 to 74, smokers with more than 20 active pack-years or weaned for less than 15 years.

Description

Inclusion Criteria:

• Women and men
• Age: 55 to 74 years old
• Smokers at more than 20 pack-years weaned for less than 15 years
• Affiliated to a social security organization

Exclusion Criteria:

• Presence of signs of PBC
• Subjects with a personal history of PBC of less than 5 years or under treatment
• Presence of serious comorbidities involving the vital prognosis at 6 months
• Subjects who have already benefited from a chest CT scan less than one year old.
• Refusal to participate in the study
• Absence of exposure to tobacco or insufficient exposure to tobacco or withdrawal > 15 years
• Patient on long-term oxygen therapy
• Metal implants (thorax, spine) which can cause a deterioration in the quality of the image of the low dose scanner
• Subject included in another study protocol

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

bronchopulmonary cancer; The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation. For subjects presenting with anomalies suggestive of PBC on the STBD, a consultation in pneumo-oncology will be planned with management corresponding to routine care.

Other: screening for bronchopulmonary cancer; The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Rate of population participation in PBC screening	Baseline

Collaborators and Investigators

• Sponsor: Centre Hospitalier Intercommunal Creteil

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): November 1, 2032

Study Registration Dates

• First Submitted: June 27, 2022
• First Submitted That Met QC Criteria: June 27, 2022
• First Posted (Actual): June 30, 2022

Study Record Updates

• Last Update Posted (Actual): June 12, 2025
• Last Update Submitted That Met QC Criteria: June 11, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: LUMASCAN-2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No